Regeneron Pharmaceuticals (REGN)

• Market cap: $70.8B
• 1 day: -7.76%
• 5 days: -10.12%
• 1 month: -9.91%
• 3 months: -9.93%
• 6 months: 3.38%
• Year to date: -13.05%
• 1 year: 18.65%
• 5 years: 39.18%
• 10 years: 79.19%
• Sector: Healthcare
• Industry: Biotechnology

About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Employees: 15,410